| Pretraživanje | Osvježi |
|
Pavan
@Pavandarlo26
|
18 h |
|
Interested candidates can ping me
#Walkin @ Hetero Biopharma #Biosimilars #Freshers pic.twitter.com/gj0BAwdEJ2
|
||
|
||
|
PepGra CRO
@pep_gra
|
27 min |
|
Guideline on adjustment for baseline covariates in clinical trials | Reason for using stratified designs - ecs.page.link/ndwtZ
#Regulatory #Pharma #MedicalDevice #Biotech #FDA #Health #LifeSciences #ClinicalTrails #Biosimilars #Clinicallife #Biostatistics pic.twitter.com/5fi2v7Ic3z
|
||
|
||
|
OncLive.com
@OncLive
|
3 h |
|
.@breastoncdoc of @UPMCHillmanCC discusses the emergence of #biosimilars in oncology and how he anticipates they will change the paradigm ow.ly/CY0l50yeL2m
|
||
|
|
||
|
Key Biologics, LLC
@keybio
|
7 h |
|
BREAKING: @Merck announces #biosimilars spin-off company + new HQ in New Jersey near parent campus. 75% of new co.’s sales expected to come from outside U.S. & involve 10k-11k employees under direction of new spin-off CEO Kevin Ali, a 30-yr. Merck veteran. pic.twitter.com/bgoEQiStUL
|
||
|
||
|
AAM
@AccessibleMeds
|
8 h |
|
How much does your state save? In 2018, generic prescription medicines saved #Indiana $6.4B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved: rxsavingsmap.org #GRxBiosimsSavingsReport #generics #biosimilars pic.twitter.com/byuXQ0LXww
|
||
|
||
|
Larry Abrams
@larrywabrams
|
8 h |
|
check out my latest post on $MCK spin out of hodge-podge product lines including #biosimilars licensed from Samsung Bioepis. Would make sense for $MRK to do another spinout of #biosimilars then do a M&E with $CHRS with better marketing org. Eliminate duplicate R&D.
|
||
|
|
||
|
Larry Abrams
@larrywabrams
|
8 h |
|
$MCK -- new hodge-podge spin out includes #biosimilars marketing org for drugs licensed from Samsung Bioepis. Would make sense for further spin out of pure #biosimilars co and buy $CHRS with better marketing org. Eliminate duplicate R&D (even I can make a bull case for $CHRS)
|
||
|
|
||
|
Larry Abrams
@larrywabrams
|
12 h |
|
#Biosimilars are much much harder to manufacturing than small molecule generics. Tossing off an FDA identified issue with $CHRS newbie European partner’s contract manufacturer process, however small, as “growing pains” ignores fact that patients’ lives are at stake here.
|
||
|
|
||
|
Crohn's and Colitis Canada
@getgutsycanada
|
12 h |
|
Looking for information about #biologics and #biosimilars? Take a peek at our #fact sheet, and learn why we advocate for patient-doctor choice 👨⚕️🏥👩⚕️.
bit.ly/2txTY23 pic.twitter.com/KJuz0tenoU
|
||
|
||
|
WT Farma
@WTFarma
|
13 h |
|
Alternate title: #Biosimilars: Let's not f*** this up twitter.com/StanMehr/statu… pic.twitter.com/pFHaK4k1nl
|
||
|
||
|
Stanton Mehr
@StanMehr
|
14 h |
|
Do you ever wonder where the US #biosimilars
market is heading, and when it might get there? I've just finished a report that answers this exact question! For drug makers, payers, prescribers, policymakers, and anyone involved in the #biosimilar industry.
bit.ly/2SihQzq
|
||
|
|
||
|
Teva Pharmaceuticals
@TevaUSA
|
15 h |
|
Go Behind the Scenes at Teva’s state-of-the-art #biopharmaceutical facility in Ulm, Germany, and meet the experts who are advancing more treatment options for patients #biopharma #biosimilars bit.ly/373iqX4 pic.twitter.com/KyGVdfkz9C
|
||
|
||
|
Neethu Sreenivasan
@neeth_sa
|
16 h |
|
Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and #Biosimilars into New Company (“NewCo”)
mrknewsroom.com/news-release/c…
|
||
|
|
||
|
Euro Biosimilars_2020
@Drug_Delivery
|
16 h |
|
Having an intention to prove yourself to the world?
Let's #Meetup Euro Biosimilars 2020
learn and Explore
#GrabThisSplendidOpportunity.#InvestinginOurselves for #BettermentofOurselves.#Hustle #HardWork #universities #students YoungResearcher #Berlin #Germany #Biosimilars #2020 pic.twitter.com/LafUwoYI51
|
||
|
||
|
En-CPhI.cn
@Pharmachina365
|
5. velj |
|
China’s Biosimilars Commercialized at an Impressive Speed. A comparison of the biosimilar accessibility in China, the EU, and the U.S. en-cphi.cn/news/show-5906… #Biosimilars pic.twitter.com/TDvAHXplMp
|
||
|
||
|
Stanton Mehr
@StanMehr
|
4. velj |
|
FDA and FTC Say They Will Work Collaboratively to Deter Anticompetitive Behavior: Actions Speak Louder Than Words wp.me/p7gt6c-4Yh #biosimilars
|
||
|
|
||
|
ThePharmaLetter
@ThePharmaLetter
|
4. velj |
|
. @US_FDA and @FTC talk tough on ensuring competition for biologics thepharmaletter.com/article/fda-an… #biosimilars
|
||
|
|
||
|
Larry Abrams
@larrywabrams
|
3. velj |
|
IMHO, your paper is the most important paper on #biosimilars in 2019. It is THE counter to @peterbachmd argument for heavy regulation (vs #biolosimilar competition) of a biologic therapeutic class once the reference drug loses it patents.
|
||
|
|
||
|
Larry Abrams
@larrywabrams
|
3. velj |
|
You state that #biosimilars are list priced 15% to 35% less than reference drug...implying that #biosimilars are cheaper than reference drugs. You should do more work on getting comparisons of net prices after rebates in the commercial market and report on that
|
||
|
|
||
|
SpeedyGonzalesi
@chaperonycon
|
1. velj |
|
With the sales growth seen so far and the likely addition of a Remicade biosimilar, Bernstein analyst Ronny Gal said "it's tough to see " Amgen 2020 biosimilar sales of less than $1.8 billion, up from $570 million in 2019. #biosimilars
biopharmadive.com/news/amgen-pfi…
|
||
|
|
||